Scarica l'app Stockscreener
2.13
1.84%
-0.04
Dopo l'orario di chiusura:
2.13
Precedente Chiudi:
$2.17
Aprire:
$2.09
Volume 24 ore:
66,668
Relative Volume:
0.37
Capitalizzazione di mercato:
$56.85M
Reddito:
$48.20M
Utile/perdita netta:
$-35.05M
Rapporto P/E:
-1.359
EPS:
-1.5673
Flusso di cassa netto:
$-13.02M
1 W Prestazione:
+0.00%
1M Prestazione:
-0.93%
6M Prestazione:
+29.88%
1 anno Prestazione:
-23.38%
Intervallo 1D:
$2.07
$2.21
Intervallo di 1 settimana:
$1.9907
$2.35
Portata 52W:
$1.06
$5.22
Celularity Inc Stock (CELU) Company Profile
Nome
Celularity Inc
Settore
Industria
Telefono
(908) 768-2170
Indirizzo
170 PARK AVE, FLORHAM PARK
Confronta CELU con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CELU
Celularity Inc
|
2.13 | 60.59M | 48.20M | -35.05M | -13.02M | -1.5673 |
|
VRTX
Vertex Pharmaceuticals Inc
|
408.61 | 105.69B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
481.07 | 61.52B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
569.17 | 60.69B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
837.28 | 50.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
318.02 | 35.25B | 4.56B | -176.77M | 225.30M | -1.7177 |
Celularity Inc Stock (CELU) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2023-01-30 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2022-12-22 | Downgrade | Oppenheimer | Outperform → Perform |
| 2022-06-22 | Iniziato | H.C. Wainwright | Buy |
| 2022-04-06 | Downgrade | Truist | Buy → Hold |
| 2022-01-28 | Iniziato | Oppenheimer | Outperform |
| 2021-11-24 | Iniziato | Morgan Stanley | Equal-Weight |
Mostra tutto
Celularity Inc Borsa (CELU) Ultime notizie
How Celularity Inc. stock performs during Fed tightening cycles2025 Major Catalysts & Smart Allocation Stock Tips - newser.com
Celularity Inc. Equity Warrant stock trendline breakdownMarket Weekly Review & Growth Focused Investment Plans - newser.com
Celularity Inc. Equity Warrant stock outlook for YEARQuarterly Portfolio Report & Low Risk Investment Opportunities - newser.com
What momentum shifts mean for Celularity Inc. Equity WarrantWeekly Volume Report & Technical Pattern Recognition Alerts - newser.com
Is Celularity Inc. Equity Warrant stock supported by strong cash flowsQuarterly Trade Review & Technical Pattern Based Buy Signals - newser.com
Published on: 2025-10-15 11:28:29 - newser.com
Multi asset correlation models including Celularity Inc. Equity WarrantDividend Hike & Real-Time Stock Entry Alerts - newser.com
Applying big data sentiment scoring on Celularity Inc. Equity Warrant2025 Biggest Moves & Short-Term Trading Opportunity Alerts - newser.com
Candlestick signals on Celularity Inc. stock todayJuly 2025 Spike Watch & Expert Approved Momentum Trade Ideas - newser.com
Can Celularity Inc. Equity Warrant stock sustain market leadershipTrade Risk Assessment & Low Volatility Stock Suggestions - newser.com
Using data models to predict Celularity Inc. stock movementEntry Point & AI Forecasted Entry/Exit Points - newser.com
How sentiment analysis helps forecast Celularity Inc.Quarterly Trade Report & Community Consensus Trade Alerts - newser.com
Is Celularity Inc. forming a bottoming baseBull Run & Real-Time Chart Breakout Alerts - newser.com
Celularity Announces Peer-Reviewed Publication of Phase 2 Clinical Trial Results Demonstrating the Safety and Efficacy of Human Placenta-Derived Cells for Diabetic Foot Ulcers Complicated by Peripheral Artery Disease - Investing News Network
Evaluating Celularity Inc. with trendline analysisShare Buyback & Scalable Portfolio Growth Ideas - newser.com
Is Celularity Inc. Equity Warrant stock cheap at current valuationWeekly Profit Analysis & Community Supported Trade Ideas - newser.com
Celularity’s diabetic foot ulcer therapy shows promise in clinical trial By Investing.com - Investing.com Canada
How to recover losses in Celularity Inc. Equity Warrant stockJuly 2025 Opening Moves & Expert Verified Stock Movement Alerts - newser.com
Published on: 2025-10-14 13:50:00 - newser.com
Celularity Inc. Announces Positive Phase 2 Results for PDA-002 in Treating Diabetic Foot Ulcers Complicated by Peripheral Artery Disease - Quiver Quantitative
Celularity Announces Peer-Reviewed Publication of Phase 2 Clinical Trial Results Demonstrating the Safety and Efficacy of Human Placenta-Derived Cells (PDA-002) for Diabetic Foot Ulcers Complicated by Peripheral Artery Disease - Stock Titan
Is Celularity Inc. stock cheap at current valuationJuly 2025 Closing Moves & Weekly High Return Forecasts - newser.com
How to track smart money flows in Celularity Inc. Equity Warrant2025 Big Picture & Verified Entry Point Signals - newser.com
Celularity Inc. Equity Warrant recovery potential after sell off2025 Earnings Surprises & Community Consensus Trade Alerts - newser.com
Published on: 2025-10-14 00:55:53 - newser.com
Analyzing Celularity Inc. with multi timeframe charts2025 Market Sentiment & Weekly High Return Opportunities - newser.com
Can Celularity Inc. stock hit analyst price targetsJuly 2025 PreEarnings & Real-Time Price Movement Reports - newser.com
Using Python tools to backtest Celularity Inc. Equity Warrant strategies2025 Earnings Impact & AI Enhanced Trading Signals - newser.com
Risk adjusted return profile for Celularity Inc. Equity Warrant analyzedMarket Weekly Review & Daily Risk Controlled Trade Plans - newser.com
Will Celularity Inc. Equity Warrant stock go up soonJuly 2025 Sentiment & Accurate Buy Signal Notifications - newser.com
How to monitor Celularity Inc. Equity Warrant with trend dashboards2025 Momentum Check & Community Supported Trade Ideas - newser.com
Celularity Inc Azioni (CELU) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Celularity Inc Azioni (CELU) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Hariri Robert J | Chief Executive Officer |
Apr 13 '25 |
Option Exercise |
0.00 |
3,281 |
0 |
21,482 |
| Haines John R | Senior Exec Vice President |
Apr 13 '25 |
Option Exercise |
0.00 |
1,641 |
0 |
29,698 |
| Beers David C | Chief Financial Officer |
Apr 13 '25 |
Option Exercise |
0.00 |
1,025 |
0 |
18,561 |
| Brigido Stephen | Pres., Functional Regeneration |
Feb 17 '25 |
Option Exercise |
0.00 |
10,000 |
0 |
11,641 |
| Beers David C | Chief Financial Officer |
Feb 17 '25 |
Option Exercise |
0.00 |
12,500 |
0 |
21,932 |
| Haines John R | Senior Exec Vice President |
Feb 17 '25 |
Option Exercise |
0.00 |
20,000 |
0 |
35,092 |
2.96%
0.09%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):